Day One

• Exploring the differentiation point of Grabody-B targeting IGF1R vs conventional TFR1-based shuttles in APOE4 populations
• Deciphering the multiple transcytosis pathways used by IGF1R-based shuttles using mechanistic animal studies
• Demonstrating how IGF1R-targeting shuttles uniquely utilize filamentous actin

• By incorporating tissue-specific binders into the AAV capsid, we have successfully engineered JUST-AAV vectors with enhanced tissue selectivity
• Introduction of targeted mutations on the capsid surface has significantly reduced off-target transduction in non-target tissues such as the liver
• JUST-AAV vectors have demonstrated high therapeutic efficacy in multiple mouse models of central nervous system diseases

A prime chance to make the most of in-person networking and forge new connections with international CNS innovators. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the conference.

• Demonstrating how AR1001 induces multiple neuroprotective effects, with potential to be disease-modifying
• Investigating the commercial and clinical variability of AR1001 under POLARIS-AD (global Phase III trial)
• Showing how AR1001 achieves simultaneous multimodal effects while maintaining an exceptional safety profile

• Demonstrating how AB-12 and AB-19 target intracellular tau neurofibrillary tangles while restoring cognitive, behavioural and neuromuscular functions
• Elucidating the mechanisms underpinning the AUTOTAC platform’s ability to reactivate dysfunctional levels of CNS autophagy
• Showcasing phase I data from AB-12 and phase II results from the AB-81 study in canine dementia

• Unravelling the mechanism of action of GPCR19 agonism
• Demonstrating simultaneous targeting of Aβ and neuroinflammation
• Reviewing results and key takeaways from the Phase I trial of NuCerin in South Korea

• Exploring the latest RNA editing approaches to target APOE, such as Rznomics’ trans-splicing-induced replacement of APOE4
• Discussing the potential of RNAi platforms to transverse the BBB and silence disease-causing genes in the brain
• Evaluating opportunities for ASOs, such as Sovargen’s SVG105, to achieve greater efficacy than conventional gene and small molecule therapies in epilepsies
• Evaluating novel exosome-based and lipid carrier platforms for CNS-targeted RNA therapeutics

• Exploring how to leverage novel modalities to target epilepsy, neurodevelopmental disorders, depression, neuromuscular diseases and more
• Referencing Angelini’s ASO-centered partnership with Sovargen
• Discussing novel formulation approaches including LNPs for enhanced CNS targeting

As the landscape of innovation in Korea is enabling greater mechanistic understanding, enhanced BBB penetration, and development towards potentially disease-modifying CNS therapies, it is more important than ever to collaborate and learn for the growth of this field. Join our dedicated poster session to share your latest data and have a first look into what your peers are working on.

• Showcasing Brainimmunex’s novel approach to rejuvenating aged brains via metabolic reprogramming
• Demonstrating how rejuvenating senescent microglia leads to normal phagocytic function
• Presenting data from in vitro screening of microglial cultures and investigations in ALS drosophila and mice models

• Deciphering how ZCS1 promotes reactivation of lysosome enzymatic function via TFEB regulation
• Demonstrating TDP-43 clearance and NfL reduction in (SOD1)-G93A mouse models
• Future directions for progressing towards GLP toxicology studies and first-in-human trials in 2027